The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)

Filter results
Date Title Content PDF
22/06/2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A.
22/06/2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share.
17/06/2021 Announcement of general shareholders’ meeting ROVI releases the information related to its General Shareholders Meeting
13/05/2021 On business and financial situation The company releases the press release related to first quarter 2021 financial results
13/05/2021 On business and financial situation ROVI releases the first quarter 2021 results presentation
13/05/2021 Announcement of general shareholders’ meeting Rovi releases the information related to its 2021 General Shareholders Meeting
29/04/2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.    
12/04/2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine.
6/04/2021 Liquidity contracts and specialists Liquidity contract: transactions conducted in the first quarter of 2021
2/03/2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States 

Pages